PDE4B Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q07343 |
---|---|
Clone Names | 80917126 |
Gene ID | 5142 |
---|---|
Other Names | cAMP-specific 3', 5'-cyclic phosphodiesterase 4B, DPDE4, PDE32, PDE4B, DPDE4 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | PDE4B (HGNC:8781) |
---|---|
Synonyms | DPDE4 |
Function | Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes (PubMed:15260978). May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents. |
Cellular Location | [Isoform PDE4B5]: Cytoplasm. Cell membrane |
Tissue Location | Expressed in brain, heart, lung and skeletal muscle (PubMed:17519386). Expressed in white blood cells (PubMed:8392015) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene was identified as a locus frequently mutated inhereditary nonpolyposis colon cancer (HNPCC). It is a human homologof the E. coli DNA mismatch repair gene mutL, consistent with thecharacteristic alterations in microsatellite sequences(RER+phenotype) found in HNPCC. Alternative splicing results inmultiple transcript variants encoding distinct isoforms. Additionaltranscript variants have been described, but their full-lengthnatures have not been determined.
References
Ling, Z.Q., et al. Cancer Lett. 297(2):244-251(2010)Qi, Y., et al. J. Biol. Chem. 285(43):33010-33017(2010)Borras, E., et al. Cancer Res. 70(19):7379-7391(2010)Mangoni, M., et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) In press :Ho-Pun-Cheung, A., et al. Pharmacogenomics J. (2010) In press :
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.